Ipca Laboratories Limited saw its stock price rise over 4% on February 13 following a robust financial performance in Q3 FY25, surpassing market estimates on key profitability metrics.
The company’s revenue from operations stood at ₹2,245.37 crore, reflecting a 9.4% year-on-year (YoY) growth from ₹2,052.85 crore in Q3 FY24. The total income for the quarter increased to ₹2,265.48 crore, up from ₹2,075.30 crore in the same period last year.
At the profitability level, net profit attributable to owners of the company surged 38% YoY to ₹248.14 crore, compared to ₹179.88 crore in the year-ago quarter. The strong profit growth was supported by improved operational performance and cost efficiencies.
Key Highlights:
- EBITDA: ₹4.63 billion vs ₹3.31 billion YoY; Estimate: ₹4.20 billion
- EBITDA Margin: 20.62% vs 16.14% YoY; Estimate: 18%
- Total Expenses: ₹1,897.56 crore, reflecting higher material and employee costs
- Tax Expenses: ₹90.59 crore compared to ₹66.53 crore last year
For the nine-month period ending December 31, 2024, Ipca reported a total revenue of ₹6,759.88 crore, registering a YoY growth of 17%. The net profit for the same period stood at ₹669.86 crore, up from ₹487.76 crore in the previous year.
The company continues to maintain its strong position in the pharmaceutical sector, with steady revenue growth and improved margins driving investor confidence.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
